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Nuclear lipid metabolism has widely been implicated in cell growth, differentiation and neoplastic transformation. Phosphoinositide-phospholipase C (PI-PLC) b-1 is a key enzyme in nuclear signal transduction, and it is involved in many cellular processes, such as proliferation and differentiation. 1 The involvement of PI-PLCb-1 in hematopoietic differentiation prompted us to investigate the role of this signaling molecule in hematological malignancies, focusing particularly on patients affected by myelodysplastic syndromes (MDS) at higher risk of evolution into acute myeloid leukemia (AML). By using fluorescence in situ hybridization (FISH) analysis, our group demonstrated, in a small number of high-risk MDS patients, 2 that subjects bearing a mono-allelic cryptic deletion of the PIPLCb-1 gene had a worse clinical outcome, as compared with patients having both alleles. In a subsequent study, it has also been shown that the expression profile of both PI-PLCb-1a and PI-PLCb-1b mRNAs, which are the two alternative splicing isoforms of PI-PLCb-1, is altered in high-risk MDS, as compared to healthy donors. 3 Interestingly, MDS cells always expressed higher levels of PI-PLCb-1b mRNA as compared to PI-PLCb-1a mRNA; this difference may reflect a specific role of PI-PLCb-1 in MDS, given that the PI-PLCb-1a splicing isoform demonstrates both nuclear and cytoplasmatic localization, while PI-PLCb-1b splicing isoform is localized only in the nucleus. Furthermore, our recent studies demonstrated that not only is Akt specifically phosphorylated in high-risk MDS patients, but also mTOR and its downstream targets are activated, 4 affecting cell survival and proliferation of MDS cells.
Azacitidine is a DNA methyltransferase inhibitor currently approved for the treatment of MDS and under experimental evaluation for other hematological malignancies. 5 Besides showing response rates of 50-80% in MDS, azacitidine has been reported to have a significant impact on the quality of life and progression into AML. 6 Nevertheless, the molecular mechanisms underlying this drug are not completely understood. Low-dose regimens with azacitidine have been assumed to act by reversing the epigenetic silencing of target genes involved in the control of cell growth and differentiation. However, although demethylation of a hypermethylated p15/ INK4B gene has been demonstrated in MDS patients treated with demethylating therapy, 7 this observation does not necessarily mean that this is the main mechanism of action of the drug in vivo. Moreover, since p15 is unlikely to be the only hypermethylated and silenced gene in MDS, it is important to examine the presence of other targets for demethylating treatment.
Here, we report on a patient diagnosed with MDS who was treated with azacitidine. After reaching a partial hematologic remission, following the International Working Group (IWG) response criteria, 8 the patient's hematological response temporarily decreased, but was subsequently restored, finally reaching a complete remission. During the therapy, the patient demonstrated an increase in PI-PLCb-1 expression, as well as a downregulation in the level of activated Akt, postulating an association between PI-PLCb-1 expression and azacitidine effectiveness.
The patient, a 60-year-old male, with a diagnosis of MDS since September 2000 and previously treated with supportive care (transfusions and deferoxamine) was started on azacitidine (75 mg/ m 2 /day for 7 days in each 28-day cycle) in September 2004. At the Letters to the Editor beginning of the treatment, the hematologic condition was: RAEB, according to the FAB classification (bone marrow blasts: 11%); RAEB-2, according to the WHO classification; and IPSS risk group: Intermediate-2. The karyotype was normal and serum erythropoietin levels were high (700 mU/mL). The patient showed an initial rise of platelet counts (245 000/mm 3 ) early after the first course, and became transfusion-independent after the fourth cycle, achieving a partial remission (that is, Hb411 g/dl) in September 2005, after 11 courses. Azacitidine was then administrated with the same schedule, as a maintenance treatment. A temporary reduction of the response (a decrease of peripheral blood counts) was subsequently demonstrated that the patient examined in this study did not bear the mono-allelic deletion of the PI-PLCb-1 gene, indicating a more favorable prognosis. 2 Interestingly, real-time PCR analyses, performed before the beginning of the treatment as described previously, 3 showed that this patient had a low expression of both PI-PLCb-1 mRNAs. During the treatment with azacitidine, the patient showed an increase in PI-PLCb-1 mRNA levels, which could be related to his clinical outcome. In fact, as Figure 1 shows, the levels of PI-PLCb-1 progressively increased up to a peak corresponding to partial remission, while they lowered during the subsequent period, when peripheral blood counts decreased. Then, after the restoration of the hematologic response, the amount of PI-PLCb-1 mRNAs started to increase again, up to a peak corresponding to complete remission. These results were confirmed also by the study of the expression of PIPLCb-1 protein, its substrate phosphatidyl-inositol 4,5-bisphosphate (PIP 2 ) and the level of activated Akt; in particular, immunocytochemical analyses were performed as described by Follo et al, 4 by using a specific rabbit polyclonal antibody to PIPLCb-1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA); mouse monoclonal to PIP 2 (Echelon Biosciences, Salt Lake City, CA, USA); and a rabbit polyclonal to Ser473 p-Akt (Cell Signalling Technology, Beverly, MA, USA). 
Pre-Treatment
A B-C D E-F G-H I-K L PI-PLCbetal p-Akt PIP 2
Figure 2
Immunocytochemical analysis of phosphoinositide-phospholipase C (PI-PLC)b-1, phosphatidyl-inositol 4,5-bisphosphate (PIP 2 ) and p-Akt. Representative immunofluorescence (original magnification Â 600) of PI-PLCb-1, PIP 2 and p-Akt immunostaining of patient's mononuclear cells during the treatment with azacitidine. Before the treatment, cells displayed a very high amount of p-Akt and a low staining for PI-PLCb-1. During the therapy (samples A-L), and particularly in correspondence to the period of partial and complete remission (sample D and L, respectively), the levels of PI-PLCb-1 augmented, whereas p-Akt decreased. Moreover, PIP 2 levels showed fluctuations correlated with the quantity of PI-PLCb-1 or p-Akt, indicating the existence of a relationship between these two molecules. Images were taken on a Zeiss Axio Imager.Z1 microscope, with 60 Â /NA 1.40 optics, coupled to a computer-driven Zeiss AxioCAM digital camera (MRm), using the Zeiss Axio Vision (version 4.5) software with constant settings of exposure. For quantification of immunoreactivity, at least 50-100 cells/slide were counted.
Our results showed fluctuating PIP 2 levels, which were inversely related to the amount of PI-PLCb-1 and directly related to the levels of activated Akt, indicating a possible correlation between these two molecules. In fact, as Figure 2 shows, when the patient displayed high-levels of activated Akt, for example before the beginning of the treatment, he demonstrated low-levels of PI-PLCb-1. On the contrary, when the expression of PI-PLCb-1 reached its highest level, that corresponded to the lowest levels of activated Akt. These molecular findings, together with the clinical data of the patient, are consistent with the hypothesis that in high-risk MDS cases azacitidine might have a direct effect on PI-PLCb-1, which could play an essential role in MDS, as well as activated Akt, whose pathways are correlated to the imbalance of the apoptotic processes in MDS cells. Moreover, it is reasonable to hypothesize that the balance between these two molecules could be directly related to PIP 2 levels.
To our knowledge, this is the first time that a correlation between azacitidine treatment and a lipid signaling pathway has been described; furthermore, this is the first report of a possible direct association between PI-PLCb-1 and activated Akt levels. Future investigations are needed to fully understand the molecular mechanisms underlying the pathogenesis of the disease and the role of azacitidine on these signaling pathways. Nevertheless, our findings have significance for high-risk MDS patients, since the altered expression of nuclear PI-PLCb-1 and the amount of activated Akt could be involved in a deregulation of the cell cycle and negatively influence cell apoptosis processes, thereby affecting the survival of primary MDS cells. Taken together, our data contribute to the further clarification of the therapeutic activity of azacitidine in high-risk MDS. Moreover, these results might pave the way for new therapeutic approaches in these patients, as the quantification of the expression of PI-PLCb-1 and levels of activated Akt could represent an attractive new predictive factor for the responsiveness to azacitidine treatments. 
